Skip to main content
Clinical Trials/NCT04799834
NCT04799834Active, not recruitingNot Applicable

Study of the Genetic Factors That Influence the Susceptibility to and Severity of COVID-19

Mario Negri Institute for Pharmacological Research1 site in 1 country1,200 target enrollmentStarted: November 30, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
1,200
Locations
1
Primary Endpoint
Identification of genetic factors affecting risk of SARS-Cov-2 infection.

Study Overview

Brief Summary

COVID-19 is a viral disease induced by infection with the novel SARS-CoV-2 coronavirus. Infection arises from the inhalation of viral particles spread by an infected individual. The main virus entry pathways are the nose and mouth mucous membranes, particularly rich in ACE2 receptors, that are used by the virus to enter cells and begin its replication.

Not all individuals who contract the virus fall ill, and most of those who do (about 70-80%) experience mild symptoms (fever, cough, headache, muscle aches, loss of taste and smell). If the immune system is unable to rapidly fight the virus back, the latter can attack the lungs, affeting oxygen absorption inside the alveoli and lead to pneumonia. This more severe form is observed in 20% of patients and can develop into even more serious complications requiring intensive care, with a high mortality rate. In severe cases (about 5%), the disease spreads to the entire body reaching the cardiovascular system and brain, with the risk of heart attacks, encephalitis and stroke, but it can also affect the liver, kidney and bowel.

Reasons why some subjects develop a highly severe disease while others have little or no symptoms at all still remain unclear. Many researchers are trying to find an answer by investigating the human genome, and the Mario Negri laboratories are also working in this direction.

The general hypothesis underlying this research project is that inter-individual genetic variations can explain the different responses to viral infection in a population, and that COVID-19 severity is, therefore, genetically determined in each infected subject.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Other

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age > 18 years

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Identification of genetic factors affecting risk of SARS-Cov-2 infection.

Time Frame: Through study completion, an average of 10 months.

Identification of the genetic determinants of COVID-19 severity.

Time Frame: Through study completion, an average of 10 months.

Identification of variants in one or more candidate gene(s) responsible for the severe manifestation of COVID-19.

Secondary Outcomes

  • Identification of polymorphic variants or mutations affecting treatment response in severe COVID-19 patients.(Through study completion, an average of 10 months.)

Investigators

Sponsor
Mario Negri Institute for Pharmacological Research
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials